Boehringer’s Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire

 
• By Joseph Haas

The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.

Development_Strategy
BI looks to external innovation to bolster its therapeutic focus areas

More from Strategy

More from Business